{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T03:41:18Z","timestamp":1793418078594,"version":"4.5.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,9,21]],"date-time":"2023-09-21T00:00:00Z","timestamp":1695254400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,9,21]],"date-time":"2023-09-21T00:00:00Z","timestamp":1695254400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005296","name":"University Hospital Regensburg","doi-asserted-by":"crossref","award":["3 00 52 04"],"award-info":[{"award-number":["3 00 52 04"]}],"id":[{"id":"10.13039\/501100005296","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100005296","name":"Universit\u00e4tsklinikum Regensburg","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005296","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Angiogenesis"],"published-print":{"date-parts":[[2024,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Extracranial arteriovenous malformations (AVMs) are regarded as rare diseases and are prone to complications such as pain, bleeding, relentless growth, and high volume of shunted blood. Due to the high vascular pressure endothelial cells of AVMs are exposed to mechanical stress. To control symptoms and lesion growth pharmacological treatment strategies are urgently needed in addition to surgery and interventional radiology. AVM cells were isolated from three patients and exposed to cyclic mechanical stretching for 24\u00a0h. Thalidomide and bevacizumab, both VEGF inhibitors, were tested for their ability to prevent the formation of circular networks and proliferation of CD31<jats:sup>+<\/jats:sup> endothelial AVM cells. Furthermore, the effect of thalidomide and bevacizumab on stretched endothelial AVM cells was evaluated. In response to mechanical stress, VEGF gene and protein expression increased in patient AVM endothelial cells. Thalidomide and bevacizumab reduced endothelial AVM cell proliferation. Bevacizumab inhibited circular network formation of endothelial AVM cells and lowered VEGF gene and protein expression, even though the cells were exposed to mechanical stress. With promising in vitro results, bevacizumab was used to treat three patients with unresectable AVMs or to prevent regrowth after incomplete resection. Bevacizumab controlled bleeding, pulsation, and pain over the follow up of eight months with no patient-reported side effects. Overall, mechanical stress increases VEGF expression in the microenvironment of AVM cells. The monoclonal VEGF antibody bevacizumab alleviates this effect, prevents circular network formation and proliferation of AVM endothelial cells in vitro. The clinical application of bevacizumab in AVM treatment demonstrates effective symptom control with no side effects.<\/jats:p>\n                <jats:p><jats:bold>Graphical abstract<\/jats:bold><\/jats:p>\n                <jats:p>Mechanical stress increases VEGF expression in endothelial AVM cells, possibly causing the VEGF upregulation in the microenvironment of AVM cells. The resulting RAS\/RAF\/MEK\/ERK signaling in leads to progression of fast-flow malformations. The monoclonal VEGF-A antibody bevacizumab alleviates this effect, prevents circular network formation and proliferation of AVM endothelial cells in vitro. Sporadically occurring slow-flow malformations (LMs, VMs) have mutations in <jats:italic>TEK<\/jats:italic> or <jats:italic>PIK3CA<\/jats:italic>. <jats:italic>TEK<\/jats:italic> encodes the endothelial receptor tyrosine kinase TIE2. Sporadic extracranial fast-flow malformations (AVMs) show mutations in <jats:italic>KRAS, BRAF<\/jats:italic> and <jats:italic>MAP2K1<\/jats:italic>, which encodes the dual specificity mitogen-activated protein kinase MEK1. Combined targeting of the molecular causes of the disease could be key to achieve symptom control and reduce lesion growth. Orange: gain-of-function; Blue, circled with orange: enhanced signaling.<\/jats:p>","DOI":"10.1007\/s10456-023-09896-3","type":"journal-article","created":{"date-parts":[[2023,9,21]],"date-time":"2023-09-21T12:02:49Z","timestamp":1695297769000},"page":"91-103","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Targeting the microenvironment in the treatment of arteriovenous malformations"],"prefix":"10.1007","volume":"27","author":[{"given":"Caroline T.","family":"Seebauer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedikt","family":"Wiens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constantin A.","family":"Hintschich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natascha","family":"Platz Batista da Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katja","family":"Evert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Haubner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Friedrich G.","family":"Kapp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Wendl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathrin","family":"Renner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Bohr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"K\u00fchnel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronika","family":"Vielsmeier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,9,21]]},"reference":[{"issue":"1","key":"9896_CR1","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s10456-022-09853-6","volume":"26","author":"PJ Smits","year":"2023","unstructured":"Smits PJ et al (2023) Endothelial cell expression of mutant Map2k1 causes vascular malformations in mice. Angiogenesis 26(1):97\u2013105. https:\/\/doi.org\/10.1007\/s10456-022-09853-6","journal-title":"Angiogenesis"},{"issue":"16","key":"9896_CR2","doi-asserted-by":"publisher","first-page":"9037","DOI":"10.3390\/ijms22169037","volume":"22","author":"K Schimmel","year":"2021","unstructured":"Schimmel K et al (2021) Arteriovenous malformations-current understanding of the pathogenesis with implications for treatment. Int J Mol Sci 22(16):9037. https:\/\/doi.org\/10.3390\/ijms22169037","journal-title":"Int J Mol Sci"},{"issue":"1","key":"9896_CR3","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/J.OTC.2017.09.003","volume":"51","author":"E Seront","year":"2018","unstructured":"Seront E et al (2018) Venous malformations of the head and neck. Otolaryngol Clin North Am 51(1):173\u2013184. https:\/\/doi.org\/10.1016\/J.OTC.2017.09.003","journal-title":"Otolaryngol Clin North Am"},{"issue":"5","key":"9896_CR4","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1007\/s40257-020-00528-w","volume":"21","author":"A Van Damme","year":"2020","unstructured":"Van Damme A et al (2020) New and emerging targeted therapies for vascular malformations. Am J Clin Dermatol 21(5):657\u2013668. https:\/\/doi.org\/10.1007\/s40257-020-00528-w","journal-title":"Am J Clin Dermatol"},{"issue":"4","key":"9896_CR5","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1097\/PRS.0b013e3181d18070","volume":"125","author":"AS Liu","year":"2010","unstructured":"Liu AS et al (2010) Extracranial arteriovenous malformations: natural progression and recurrence after treatment. Plast Reconstr Surg 125(4):1185\u20131194. https:\/\/doi.org\/10.1097\/PRS.0b013e3181d18070","journal-title":"Plast Reconstr Surg"},{"issue":"11","key":"9896_CR6","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1016\/j.jvir.2012.08.012","volume":"23","author":"KB Park","year":"2012","unstructured":"Park KB et al (2012) Predictive factors for response of peripheral arteriovenous malformations to embolization therapy: analysis of clinical data and imaging findings. J Vasc Interv Radiol 23(11):1478\u20131486. https:\/\/doi.org\/10.1016\/j.jvir.2012.08.012","journal-title":"J Vasc Interv Radiol"},{"issue":"1","key":"9896_CR7","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s13023-018-0982-4","volume":"14","author":"E Buscarini","year":"2019","unstructured":"Buscarini E et al (2019) Safety of thalidomide and bevacizumab in patients with hereditary hemorrhagic telangiectasia. Orphanet J Rare Dis 14(1):28. https:\/\/doi.org\/10.1186\/s13023-018-0982-4","journal-title":"Orphanet J Rare Dis"},{"issue":"12","key":"9896_CR8","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1177\/1947601911423031","volume":"2","author":"M Shibuya","year":"2011","unstructured":"Shibuya M (2011) Vascular Endothelial Growth Factor (VEGF) and its Receptor (VEGFR) signaling in angiogenesis: a crucial target for anti- and pro-angiogenic therapies. Genes Cancer 2(12):1097\u20131105. https:\/\/doi.org\/10.1177\/1947601911423031","journal-title":"Genes Cancer"},{"key":"9896_CR9","doi-asserted-by":"publisher","DOI":"10.1007\/s10456-023-09876-7","author":"AC Dudley","year":"2023","unstructured":"Dudley AC, Griffioen AW (2023) Pathological angiogenesis: mechanisms and therapeutic strategies. Angiogenesis. https:\/\/doi.org\/10.1007\/s10456-023-09876-7","journal-title":"Angiogenesis"},{"issue":"9","key":"9896_CR10","doi-asserted-by":"publisher","first-page":"4082","DOI":"10.1073\/pnas.91.9.4082","volume":"91","author":"RJ D\u2019Amato","year":"1994","unstructured":"D\u2019Amato RJ et al (1994) Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci 91(9):4082\u20134085. https:\/\/doi.org\/10.1073\/pnas.91.9.4082","journal-title":"Proc Natl Acad Sci"},{"issue":"22","key":"9896_CR11","doi-asserted-by":"publisher","first-page":"2558","DOI":"10.1016\/j.lfs.2005.10.016","volume":"78","author":"J Komorowski","year":"2006","unstructured":"Komorowski J et al (2006) Effect of thalidomide affecting VEGF secretion, cell migration, adhesion and capillary tube formation of human endothelial EA.hy 926 cells. Life Sci 78(22):2558\u20132563. https:\/\/doi.org\/10.1016\/j.lfs.2005.10.016","journal-title":"Life Sci"},{"issue":"4","key":"9896_CR12","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1007\/s00408-013-9477-1","volume":"191","author":"C-M Tseng","year":"2013","unstructured":"Tseng C-M et al (2013) The suppression effects of thalidomide on human lung fibroblasts: cell proliferation, vascular endothelial growth factor release, and collagen production. Lung 191(4):361\u2013368. https:\/\/doi.org\/10.1007\/s00408-013-9477-1","journal-title":"Lung"},{"key":"9896_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2020.155022","author":"P Wei","year":"2020","unstructured":"Wei P et al (2020) Bevacizumab has bidirectional regulatory effects on the secretion of basic fibroblast growth factor in glioma cells. Cytokine. https:\/\/doi.org\/10.1016\/j.cyto.2020.155022","journal-title":"Cytokine"},{"issue":"2","key":"9896_CR14","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/s00280-016-3079-6","volume":"78","author":"K Han","year":"2016","unstructured":"Han K et al (2016) Population pharmacokinetics of bevacizumab in cancer patients with external validation. Cancer Chemother Pharmacol 78(2):341\u2013351. https:\/\/doi.org\/10.1007\/s00280-016-3079-6","journal-title":"Cancer Chemother Pharmacol"},{"issue":"9","key":"9896_CR15","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1111\/j.1349-7006.2002.tb02480.x","volume":"93","author":"T Kakimoto","year":"2002","unstructured":"Kakimoto T et al (2002) Thalidomide for the treatment of refractory multiple myeloma: association of plasma concentrations of thalidomide and angiogenic growth factors with clinical outcome. Jpn J Cancer Res 93(9):1029\u20131036. https:\/\/doi.org\/10.1111\/j.1349-7006.2002.tb02480.x","journal-title":"Jpn J Cancer Res"},{"issue":"4","key":"9896_CR16","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1177\/1945892418768588","volume":"32","author":"AA Halderman","year":"2018","unstructured":"Halderman AA et al (2018) Bevacizumab for epistaxis in hereditary hemorrhagic telangiectasia: an evidence-based review. Am J Rhinol Allergy 32(4):258\u2013268. https:\/\/doi.org\/10.1177\/1945892418768588","journal-title":"Am J Rhinol Allergy"},{"issue":"1","key":"9896_CR17","doi-asserted-by":"publisher","first-page":"115","DOI":"10.5999\/aps.2021.00626","volume":"49","author":"JY Ryu","year":"2022","unstructured":"Ryu JY et al (2022) Wall shear stress on vascular smooth muscle cells exerts angiogenic effects on extracranial arteriovenous malformations. Arch Plast Surg 49(1):115\u2013120. https:\/\/doi.org\/10.5999\/aps.2021.00626","journal-title":"Arch Plast Surg"},{"issue":"1","key":"9896_CR18","doi-asserted-by":"publisher","first-page":"16612","DOI":"10.1038\/s41598-022-21217-0","volume":"12","author":"T Wei","year":"2022","unstructured":"Wei T et al (2022) Extracranial arteriovenous malformations demonstrate dysregulated TGF-\u03b2\/BMP signaling and increased circulating TGF-\u03b21. Sci Rep 12(1):16612. https:\/\/doi.org\/10.1038\/s41598-022-21217-0","journal-title":"Sci Rep"},{"issue":"6","key":"9896_CR19","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1038\/nm0603-669","volume":"9","author":"N Ferrara","year":"2003","unstructured":"Ferrara N et al (2003) The biology of VEGF and its receptors. Nat Med 9(6):669\u2013676. https:\/\/doi.org\/10.1038\/nm0603-669","journal-title":"Nat Med"},{"issue":"6","key":"9896_CR20","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1016\/j.cell.2019.01.021","volume":"176","author":"RS Apte","year":"2019","unstructured":"Apte RS et al (2019) VEGF in signaling and disease: beyond discovery and development. Cell 176(6):1248\u20131264. https:\/\/doi.org\/10.1016\/j.cell.2019.01.021","journal-title":"Cell"},{"issue":"6","key":"9896_CR21","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1002\/ana.22348","volume":"69","author":"EJ Walker","year":"2011","unstructured":"Walker EJ et al (2011) Arteriovenous malformation in the adult mouse brain resembling the human disease. Ann Neurol 69(6):954\u2013962. https:\/\/doi.org\/10.1002\/ana.22348","journal-title":"Ann Neurol"},{"issue":"5","key":"9896_CR22","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.3171\/2019.1.JNS183112","volume":"132","author":"P Cheng","year":"2019","unstructured":"Cheng P et al (2019) Effect of elevation of vascular endothelial growth factor level on exacerbation of hemorrhage in mouse brain arteriovenous malformation. J Neurosurg 132(5):1566\u20131573. https:\/\/doi.org\/10.3171\/2019.1.JNS183112","journal-title":"J Neurosurg"},{"issue":"6","key":"9896_CR23","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1038\/s44161-022-00080-2","volume":"1","author":"LM Boon","year":"2022","unstructured":"Boon LM et al (2022) Case report study of thalidomide therapy in 18 patients with severe arteriovenous malformations. Nat Cardiovasc Res 1(6):562\u2013567. https:\/\/doi.org\/10.1038\/s44161-022-00080-2","journal-title":"Nat Cardiovasc Res"},{"issue":"6","key":"9896_CR24","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1038\/nm0603-677","volume":"9","author":"CW Pugh","year":"2003","unstructured":"Pugh CW, Ratcliffe PJ (2003) Regulation of angiogenesis by hypoxia: role of the HIF system. Nat Med 9(6):677\u2013684. https:\/\/doi.org\/10.1038\/nm0603-677","journal-title":"Nat Med"},{"issue":"1","key":"9896_CR25","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1038\/cr.2008.326","volume":"19","author":"M-J Goumans","year":"2009","unstructured":"Goumans M-J et al (2009) TGF-\u03b2 signaling in vascular biology and dysfunction. Cell Res 19(1):116\u2013127. https:\/\/doi.org\/10.1038\/cr.2008.326","journal-title":"Cell Res"},{"issue":"4","key":"9896_CR26","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1038\/nm0410-370","volume":"16","author":"RJ Akhurst","year":"2010","unstructured":"Akhurst RJ (2010) Taking thalidomide out of rehab. Nat Med 16(4):370\u2013372. https:\/\/doi.org\/10.1038\/nm0410-370","journal-title":"Nat Med"},{"issue":"9","key":"9896_CR27","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1038\/sj.leu.2403852","volume":"19","author":"D Ribatti","year":"2005","unstructured":"Ribatti D, Vacca A (2005) Therapeutic renaissance of thalidomide in the treatment of haematological malignancies. Leukemia 19(9):1525\u20131531. https:\/\/doi.org\/10.1038\/sj.leu.2403852","journal-title":"Leukemia"},{"issue":"5","key":"9896_CR28","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1161\/STROKEAHA.117.020356","volume":"49","author":"W Zhu","year":"2018","unstructured":"Zhu W et al (2018) Thalidomide reduces hemorrhage of brain arteriovenous malformations in a mouse model. Stroke 49(5):1232\u20131240. https:\/\/doi.org\/10.1161\/STROKEAHA.117.020356","journal-title":"Stroke"},{"issue":"4","key":"9896_CR29","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1038\/nm.2131","volume":"16","author":"F Lebrin","year":"2010","unstructured":"Lebrin F et al (2010) Thalidomide stimulates vessel maturation and reduces epistaxis in individuals with hereditary hemorrhagic telangiectasia. Nat Med 16(4):420\u2013428. https:\/\/doi.org\/10.1038\/nm.2131","journal-title":"Nat Med"},{"issue":"2","key":"9896_CR30","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1111\/joim.12832","volume":"285","author":"H Al-Samkari","year":"2019","unstructured":"Al-Samkari H et al (2019) Systemic bevacizumab for the treatment of chronic bleeding in hereditary haemorrhagic telangiectasia. J Intern Med 285(2):223\u2013231. https:\/\/doi.org\/10.1111\/joim.12832","journal-title":"J Intern Med"},{"issue":"1","key":"9896_CR31","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s13023-019-1281-4","volume":"15","author":"F Robert","year":"2020","unstructured":"Robert F et al (2020) Future treatments for hereditary hemorrhagic telangiectasia. Orphanet J Rare Dis 15(1):4. https:\/\/doi.org\/10.1186\/s13023-019-1281-4","journal-title":"Orphanet J Rare Dis"},{"issue":"3","key":"9896_CR32","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1016\/j.ajhg.2017.01.018","volume":"100","author":"JA Couto","year":"2017","unstructured":"Couto JA et al (2017) Somatic MAP2K1 mutations are associated with extracranial arteriovenous malformation. Am J Hum Genet 100(3):546\u2013554. https:\/\/doi.org\/10.1016\/j.ajhg.2017.01.018","journal-title":"Am J Hum Genet"},{"issue":"3","key":"9896_CR33","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1056\/NEJMoa1709449","volume":"378","author":"SI Nikolaev","year":"2018","unstructured":"Nikolaev SI et al (2018) Somatic activating KRAS mutations in arteriovenous malformations of the brain. N Engl J Med 378(3):250\u2013261. https:\/\/doi.org\/10.1056\/NEJMoa1709449","journal-title":"N Engl J Med"},{"key":"9896_CR34","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2019-3206","author":"EA Edwards","year":"2020","unstructured":"Edwards EA et al (2020) Monitoring arteriovenous malformation response to genotype-targeted therapy. Pediatrics. https:\/\/doi.org\/10.1542\/peds.2019-3206","journal-title":"Pediatrics"},{"issue":"2","key":"9896_CR35","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1001\/jamadermatol.2018.4653","volume":"155","author":"R Lekwuttikarn","year":"2019","unstructured":"Lekwuttikarn R et al (2019) Genotype-guided medical treatment of an arteriovenous malformation in a child. JAMA Dermatol 155(2):256\u2013257. https:\/\/doi.org\/10.1001\/jamadermatol.2018.4653","journal-title":"JAMA Dermatol"},{"issue":"1","key":"9896_CR36","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1161\/CIRCRESAHA.121.318145","volume":"129","author":"A Queisser","year":"2021","unstructured":"Queisser A et al (2021) Genetic basis and therapies for vascular anomalies. Circ Res 129(1):155\u2013173. https:\/\/doi.org\/10.1161\/CIRCRESAHA.121.318145","journal-title":"Circ Res"},{"issue":"5","key":"9896_CR37","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1111\/jth.15715","volume":"20","author":"H Al-Samkari","year":"2022","unstructured":"Al-Samkari H, Eng W (2022) A precision medicine approach to hereditary hemorrhagic telangiectasia and complex vascular anomalies. J Thromb Haemost 20(5):1077\u20131088. https:\/\/doi.org\/10.1111\/jth.15715","journal-title":"J Thromb Haemost"},{"key":"9896_CR38","doi-asserted-by":"publisher","DOI":"10.1172\/JCI151109","author":"CT Seebauer","year":"2022","unstructured":"Seebauer CT et al (2022) Non-beta blocker enantiomers of propranolol and atenolol inhibit vasculogenesis in infantile hemangioma. J Clin Invest. https:\/\/doi.org\/10.1172\/JCI151109","journal-title":"J Clin Invest"},{"issue":"7","key":"9896_CR39","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1038\/sj.bjc.6603678","volume":"96","author":"RAA Mohammed","year":"2007","unstructured":"Mohammed RAA et al (2007) Prognostic significance of vascular endothelial cell growth factors -A, -C and -D in breast cancer and their relationship with angio- and lymphangiogenesis. Br J Cancer 96(7):1092\u20131100. https:\/\/doi.org\/10.1038\/sj.bjc.6603678","journal-title":"Br J Cancer"},{"issue":"9","key":"9896_CR40","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1001\/jama.2012.250","volume":"307","author":"S Dupuis-Girod","year":"2012","unstructured":"Dupuis-Girod S et al (2012) Bevacizumab in patients with hereditary hemorrhagic telangiectasia and severe hepatic vascular malformations and high cardiac output. JAMA 307(9):948\u2013955. https:\/\/doi.org\/10.1001\/jama.2012.250","journal-title":"JAMA"},{"issue":"2","key":"9896_CR41","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1007\/s00405-011-1721-9","volume":"269","author":"C Rohrmeier","year":"2012","unstructured":"Rohrmeier C et al (2012) A retrospective analysis of low dose, intranasal injected bevacizumab (Avastin) in hereditary haemorrhagic telangiectasia. Eur Arch Oto-Rhino-Laryngology 269(2):531\u2013536. https:\/\/doi.org\/10.1007\/s00405-011-1721-9","journal-title":"Eur Arch Oto-Rhino-Laryngology"},{"issue":"1","key":"9896_CR42","doi-asserted-by":"publisher","first-page":"3","DOI":"10.4193\/Rhin17.166","volume":"56","author":"P Stokes","year":"2018","unstructured":"Stokes P, Rimmer J (2018) Intranasal bevacizumab in the treatment of HHT -related epistaxis: a systematic review. Rhinology 56(1):3\u201310. https:\/\/doi.org\/10.4193\/Rhin17.166","journal-title":"Rhinology"}],"container-title":["Angiogenesis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10456-023-09896-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10456-023-09896-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10456-023-09896-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,24]],"date-time":"2024-02-24T15:14:52Z","timestamp":1708787692000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10456-023-09896-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,21]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["9896"],"URL":"https:\/\/doi.org\/10.1007\/s10456-023-09896-3","relation":{},"ISSN":["0969-6970","1573-7209"],"issn-type":[{"value":"0969-6970","type":"print"},{"value":"1573-7209","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,21]]},"assertion":[{"value":"12 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 September 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no financial interests or conflicts of interest to declare in relation to the content of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The patients or the parents of the patient provided written informed consent for use of the patient\u2019s images, imaging, clinical data, tissue samples and patient history.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Patient consent"}}]}}